The increased interactions between tumor/innate (microglia/myeloid) and CD4+ T cells also promoted the memory CD4+ T-cell differentiation that was modulated by the IL6ra-Bcl-6 axis and the proper Bcl-6 expression over the course of treatment, leading to long-term anti-tumor immunity and survival benefit (Fig. 6k). Here, BCL6 is linked to neoplasm.